1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole has been researched along with Burkitt Lymphoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daniels, I; Haynes, AP; Turzanski, J | 1 |
1 other study(ies) available for 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole and Burkitt Lymphoma
| Article | Year |
|---|---|
A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Burkitt Lymphoma; Calcium; Calcium Channel Blockers; Caspases; Cell Death; Cell Line; Cell Membrane; Dantrolene; Endoplasmic Reticulum; Flow Cytometry; Humans; Imidazoles; Inositol 1,4,5-Trisphosphate Receptors; Macrocyclic Compounds; Oxazoles; Rituximab; Ryanodine | 2008 |